No products in the cart.
Mouse Monoclonal RUNX1 antibody [2B5] (STJ98372)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:10000
Recommended protocols: check protocols
Click or hover above images to see image description for RUNX1 Monoclonal Antibody.
Check alternative names for the antibodyExpand
RUNX1 antibody, AML1 antibody, CBFA2 antibody,|Acute myeloid leukemia 1 antibody|RUNX 1 antibody|Runx1 antibody|RUNX1_HUMAN antibody|SL3 3 enhancer factor 1 alpha B subunit antibody|SL3-3 enhancer factor 1 alpha B subunit antibody|SL3/AKV core binding factor alpha B subunit antibody|SL3/AKV core-binding factor alpha B subunit antibody|Anti-RUNX1 / AML1 antibody – ChIP Grade (ab23980)
SCBT cat No: sc-293146|sc-137150|sc-137222|sc-271047|sc-271020|sc-137212|
RUNX1 Monoclonal Antibody
|Catalogue No.|| |
RUNX1 Monoclonal Antibody detects endogenous levels of RUNX1 protein.
Synthesized peptide of human RUNX1
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:10000
RUNX1 Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.
RUNX1 Antibody was purified using affinity purification.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Runt-related transcription factor 1 antibody, Acute myeloid leukemia 1 protein antibody, Core-binding factor subunit alpha-2 antibody, CBF-alpha-2 antibody, Oncogene AML-1 antibody, Polyomavirus enhancer-binding protein 2 alpha B subunit antibody, PEA2-alpha B antibody, PEBP2-alpha B antibody, SL3-3 enhancer factor 1 alpha B subunit antibody, SL3/AKV core-binding factor alpha B subunit antibody
|Protein names|| |
Runt-related transcription factor 1 , Acute myeloid leukemia 1 protein , Core-binding factor subunit alpha-2 , CBF-alpha-2 , Oncogene AML-1 , Polyomavirus enhancer-binding protein 2 alpha B subunit , PEA2-alpha B , PEBP2-alpha B , SL3-3 enhancer factor 1 alpha B subunit , SL3/AKV core-binding factor alpha B subunit
|Protein function|| |
CBF binds to the core site, 5′-PYGPYGGT-3′, of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells .
|Protein tissue specificity|| |
Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
|Involvement in disease|| |
Note: A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.; Note: A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.; Note: A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.; Note: A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3′-end of TEL to the alternate 5′-exon of AML-1H.; Note: A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.; Familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Note: A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.; Note: A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.; Note: A chromosomal aberration involving RUNX1/AML1 is found in acute myeloid leukemia. Translocation t(20;21)(q11;q22) with CBFA2T2. .
|Protein sequence and domain|| |
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. / Contains 1 Runt domain.
|Protein post-translational modifications|| |
Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with KAT6A. / Methylated. / Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when associated with CBFB and DNA. This phosphorylation promotes subsequent EP300 phosphorylation.
|Protein cellular localization|| |
AntibodyPlus can customize RUNX1 Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: